Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial
Authors' conclusion
Unlike metformin, imeglimin enhances GIP secretion as well as GLP-1 secretion, in addition to its direct insulinotropic mechanism of glucose control, emphasizing its potential as a therapeutic option in the treatment of patients with diabetes.
Study context
- Population
- Patients with T2D, drug-naïve or on a single oral hypoglycaemic agent (8-week washout before randomization)
- Comparison
- Imeglimin vs metformin
Methodological detailsexploratory, single-centre, open-label, OGTT before treatment and after 12 and 24 weeks
- Exploratory
- Single-centre
- Open-label
- OGTT before treatment and after 12 and 24 weeks
Primary result
As reported in the abstract
HbA1c reduction · 24 weeks
- Reduction in HbA1c similar in IME and MET
Further findings
OGTT post-challenge glucose and insulin
- Comparable decrease in post-challenge glucose excursion in both groups
- Insulin levels increased only with IME
Incretins (GLP-1, GIP)
- Total and active GLP-1 increased with both IME and MET
- Total and active GIP increased only with IME
Correlation of insulin increase with incretins in IME · 12 and 24 weeks
- Insulin increase positively correlated with GLP-1 increase at 12 weeks; only with GIP increase at 24 weeks
Original publication
Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial. Diabetes Obes Metab. Published 26 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →